[go: up one dir, main page]

SI3053932T1 - Novi CTLA4-IG imunoadhezini - Google Patents

Novi CTLA4-IG imunoadhezini

Info

Publication number
SI3053932T1
SI3053932T1 SI201131924T SI201131924T SI3053932T1 SI 3053932 T1 SI3053932 T1 SI 3053932T1 SI 201131924 T SI201131924 T SI 201131924T SI 201131924 T SI201131924 T SI 201131924T SI 3053932 T1 SI3053932 T1 SI 3053932T1
Authority
SI
Slovenia
Prior art keywords
immunoadhesins
novel ctla4
ctla4
novel
Prior art date
Application number
SI201131924T
Other languages
English (en)
Inventor
Gregory A. Lazar
Matthew J. Bernett
Original Assignee
Xencor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor, Inc. filed Critical Xencor, Inc.
Publication of SI3053932T1 publication Critical patent/SI3053932T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
SI201131924T 2010-02-19 2011-02-22 Novi CTLA4-IG imunoadhezini SI3053932T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30631110P 2010-02-19 2010-02-19
US33480610P 2010-05-14 2010-05-14
US41230910P 2010-11-10 2010-11-10
EP15198516.5A EP3053932B1 (en) 2010-02-19 2011-02-22 Novel ctla4-ig immunoadhesins

Publications (1)

Publication Number Publication Date
SI3053932T1 true SI3053932T1 (sl) 2021-01-29

Family

ID=44483626

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201131924T SI3053932T1 (sl) 2010-02-19 2011-02-22 Novi CTLA4-IG imunoadhezini
SI201130917A SI2536745T1 (sl) 2010-02-19 2011-02-22 Novi imunoadhezini CTLA4-Ig

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201130917A SI2536745T1 (sl) 2010-02-19 2011-02-22 Novi imunoadhezini CTLA4-Ig

Country Status (19)

Country Link
US (7) US8329867B2 (sl)
EP (2) EP3053932B1 (sl)
JP (1) JP5705242B2 (sl)
KR (1) KR101926663B1 (sl)
CN (3) CN106432473B (sl)
AU (2) AU2011217770B2 (sl)
CA (1) CA2790487C (sl)
CY (2) CY1118001T1 (sl)
DK (2) DK2536745T3 (sl)
ES (2) ES2826894T3 (sl)
HR (2) HRP20160938T1 (sl)
HU (2) HUE030100T2 (sl)
LT (2) LT2536745T (sl)
PL (2) PL3053932T3 (sl)
PT (1) PT3053932T (sl)
RS (1) RS61136B1 (sl)
SI (2) SI3053932T1 (sl)
SM (2) SMT202000572T1 (sl)
WO (1) WO2011103584A2 (sl)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
HRP20240722T1 (hr) 2008-04-11 2024-08-30 Chugai Seiyaku Kabushiki Kaisha Molekula koja se veže na antigene, koja se može ponavljano vezati na dvje ili više molekula antigena
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2011066501A1 (en) 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
RS61136B1 (sr) 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
TWI667346B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
KR101536151B1 (ko) * 2012-01-31 2015-07-14 서울대학교산학협력단 새로운 ＣＴＬＡ-４ＩｇＧ 융합 단백질
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
AU2013260172B2 (en) 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
EP2856159A4 (en) 2012-06-01 2016-04-13 Momenta Pharmaceuticals Inc METHODS RELATING TO DENOSUMAB
JP6501521B2 (ja) 2012-08-24 2019-04-17 中外製薬株式会社 ＦｃγＲＩＩｂ特異的Ｆｃ領域改変体
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3017048A4 (en) * 2013-07-01 2017-05-17 University of Maryland, College Park Fc coupled compositions and methods of their use
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
AU2015292678B2 (en) 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
JP6909153B2 (ja) 2014-08-05 2021-07-28 アポロミクス インコーポレイテッド 抗ｐｄ−ｌ１抗体
MY192824A (en) * 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
ME03806B (me) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Antitela protiv cd73 i njihova upotreba
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
MX2017007744A (es) 2014-12-23 2017-09-05 Bristol Myers Squibb Co Anticuerpos contra el inmunorreceptor de celulas t con dominios de inmunoglobulina y de porcion inhibidora con base en tirosina del inmumorreceptor (tigit).
TWI691512B (zh) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Ｆｃ融合高親和性ＩｇＥ受體α鏈
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
ES2905525T3 (es) 2015-05-06 2022-04-11 Snipr Tech Ltd Alteración de poblaciones microbianas y modificación de la microbiota
FR3035879B1 (fr) * 2015-05-07 2025-02-28 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle modifiee
SI3303396T1 (sl) 2015-05-29 2023-01-31 Bristol-Myers Squibb Company Protitelesa proti OX40 in njihova uporaba
BR112017028353A2 (pt) 2015-06-29 2018-09-04 The Rockfeller University anticorpos para cd40 com atividade agonista melhorada
TWI733685B (zh) * 2015-07-23 2021-07-21 德商包林格因蓋爾漢國際股份有限公司 靶向il-23a與b細胞活化因子(baff)之化合物及其用途
LT3370733T (lt) 2015-11-02 2021-10-25 Board Of Regents, The University Of Texas System Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
US20190038713A1 (en) 2015-11-07 2019-02-07 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
BR112018067368A2 (pt) 2016-03-04 2019-01-15 Bristol-Myers Squibb Company terapia de combinação com anticorpos anti-cd73
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
BR112018072286A2 (pt) 2016-04-29 2019-02-12 Yale University medida direcionada de atividade transcricional relacionada a receptores de hormônios
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
ES2971881T3 (es) 2016-08-19 2024-06-10 Beigene Switzerland Gmbh Combinación de zanubrutinib con un anticuerpo anti-cd20 o anti-pd-1 para su uso en el tratamiento del cáncer
CN110267651B (zh) 2016-09-27 2023-09-01 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
KR102661905B1 (ko) 2016-10-12 2024-04-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tusc2 면역요법을 위한 방법 및 조성물
EP3538112A4 (en) 2016-11-09 2020-09-02 Musc Foundation for Research Development CD38-NAD + REGULATED METABOLIC AXIS IN ANTITUMOR IMMUNOTHERAPY
TWI782931B (zh) 2016-11-17 2022-11-11 美國德州系統大學評議委員會 具有對抗帶有egfr或her2外顯子20突變之癌細胞之抗腫瘤活性的化合物
KR20190112263A (ko) 2016-12-12 2019-10-04 멀티비르 인코포레이티드 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물
WO2018137681A1 (en) 2017-01-25 2018-08-02 Beigene, Ltd. Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
EP3586136B1 (en) 2017-02-24 2023-11-08 Board Of Regents, The University Of Texas System Assay for detection of early stage pancreatic cancer
US12116412B2 (en) 2017-03-03 2024-10-15 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
CN110662758A (zh) * 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2018218056A1 (en) 2017-05-25 2018-11-29 Birstol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3634584B1 (en) 2017-06-09 2024-09-18 Providence Health & Services - Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CA3070789A1 (en) * 2017-08-10 2019-02-14 Grifols Diagnostic Solutions Inc. Compositions, methods and/or kits comprising a recombinant human cd38-extracellular domain
CN111801347A (zh) * 2017-10-10 2020-10-20 高山免疫科学股份有限公司 Ctla-4变体免疫调节蛋白和其用途
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
EP3707165A4 (en) 2017-11-07 2021-09-08 The Board of Regents of The University of Texas System TARGETING LILRB4 WITH CAR-T OR CAR-NK CELLS IN CANCER TREATMENT
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
WO2019173223A1 (en) * 2018-03-05 2019-09-12 New York University Induction and enhancement of antitumor immunity involving sindbis virus vectors expressing immune checkpoint proteins
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
AU2019246043B2 (en) 2018-03-25 2024-07-04 Snipr Biome Aps. Treating and preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202009498RA (en) 2018-03-27 2020-10-29 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
SG11202011353XA (en) * 2018-05-25 2020-12-30 Dr Reddys Laboratories Ltd Stable fusion protein formulation
KR20210124179A (ko) * 2018-11-02 2021-10-14 베이징 브이디제이바이오 컴퍼니 리미티드 변형된 ctla4 및 이의 사용 방법
JP7630832B2 (ja) 2018-11-19 2025-02-18 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｃａｒおよびｔｃｒ形質導入用のモジュール式ポリシストロニックベクター
CN113348177A (zh) 2018-11-28 2021-09-03 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
CA3121210A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
CA3138348A1 (en) 2019-05-09 2020-11-12 FUJIFILM Cellular Dynamics, Inc. Methods for the production of hepatocytes
EP3968971A1 (en) 2019-05-17 2022-03-23 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
SI3993876T1 (sl) 2019-07-01 2025-02-28 Tonix Pharma Limited Protitelesa anti-cd154 in njihova uporaba
JP2022545106A (ja) * 2019-08-22 2022-10-25 シダラ セラピューティクス インコーポレーテッド バリアントｆｃドメイン及びその使用
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
WO2021142280A1 (en) 2020-01-10 2021-07-15 Modernatx, Inc. Methods of making tolerogenic dendritic cells
AU2021213812A1 (en) 2020-01-30 2022-08-04 Modernatx, Inc. mRNAs encoding metabolic reprogramming polypeptides and uses thereof
CA3168337A1 (en) 2020-02-17 2021-08-26 Marie-Andree Forget Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021220251A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
JP2023526416A (ja) 2020-05-21 2023-06-21 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｖｇｌｌ１特異性を有するｔ細胞受容体およびその使用法
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2022150452A1 (en) 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
JP2024503480A (ja) 2021-01-19 2024-01-25 ウィリアム マーシュ ライス ユニバーシティ ポリペプチドの骨特異的送達法
KR20230169147A (ko) * 2021-03-11 2023-12-15 더 메서디스트 하스피틀 질환 치료를 위한 방법 및 조성물
WO2022261018A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
EP4351588A1 (en) 2021-06-11 2024-04-17 Sage Therapeutics, Inc. Neuroactive steroid for the treatment of alzheimer's disease
JP2024531910A (ja) 2021-08-04 2024-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
MX2024004122A (es) 2021-10-05 2024-05-13 Cytovia Therapeutics Llc Células citolíticas (asesinas) naturales y métodos de uso de las mismas.
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
WO2023070160A1 (en) * 2021-10-28 2023-05-04 Monash University Variant ctla4 proteins
US20250059230A1 (en) * 2021-12-17 2025-02-20 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins
WO2023211972A1 (en) 2022-04-28 2023-11-02 Medical University Of South Carolina Chimeric antigen receptor modified regulatory t cells for treating cancer
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517806A (ja) * 2000-07-03 2004-06-17 ブリストル−マイヤーズ　スクイブ　カンパニー 可溶性ｃｔｌａ４分子を使用するリウマチ疾患の処置方法
EP1368059A1 (en) * 2001-01-26 2003-12-10 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CN1443850A (zh) * 2002-03-08 2003-09-24 重庆立丹(集团)药业科技开发有限公司 重组人ctla4胞外区蛋白的制备方法及其所得产品和用途
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN101519451B (zh) * 2005-04-05 2011-05-25 上海中信国健药业股份有限公司 重组人sCTLA4-Ig融合蛋白基因及其药物组合物
LT1868635T (lt) * 2005-04-06 2017-07-10 Bristol-Myers Squibb Company Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
PL2222697T3 (pl) * 2007-11-01 2013-05-31 Astellas Pharma Inc Immunosupresyjne polipeptydy i kwasy nukleinowe
EP4269443A3 (en) * 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
RS61136B1 (sr) * 2010-02-19 2020-12-31 Xencor Inc Novi ctla4-ig imunoadhezini
US8642557B2 (en) * 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses

Also Published As

Publication number Publication date
JP2013520176A (ja) 2013-06-06
RS61136B1 (sr) 2020-12-31
WO2011103584A2 (en) 2011-08-25
SMT201600289B (it) 2016-11-10
US20190127437A1 (en) 2019-05-02
CA2790487C (en) 2020-10-06
US20160264643A1 (en) 2016-09-15
CN103038251B (zh) 2016-08-17
DK3053932T3 (da) 2020-10-19
US11352412B2 (en) 2022-06-07
EP3053932B1 (en) 2020-07-22
EP3053932A1 (en) 2016-08-10
DK2536745T3 (en) 2016-08-22
US20140112924A1 (en) 2014-04-24
AU2016202816A1 (en) 2016-05-26
US8329867B2 (en) 2012-12-11
EP2536745B1 (en) 2016-05-11
US9371397B2 (en) 2016-06-21
LT2536745T (lt) 2016-09-26
PL3053932T3 (pl) 2021-03-08
CN113372451A (zh) 2021-09-10
HUE030100T2 (en) 2017-04-28
US20110287032A1 (en) 2011-11-24
KR101926663B1 (ko) 2018-12-07
LT3053932T (lt) 2020-11-10
CN103038251A (zh) 2013-04-10
CN106432473A (zh) 2017-02-22
AU2011217770B2 (en) 2016-02-04
US20210230250A1 (en) 2021-07-29
CN113372451B (zh) 2024-12-03
CY1118001T1 (el) 2017-05-17
KR20120120993A (ko) 2012-11-02
AU2016202816B2 (en) 2018-01-04
EP2536745A2 (en) 2012-12-26
PL2536745T3 (pl) 2017-01-31
SMT202000572T1 (it) 2021-01-05
PT3053932T (pt) 2020-10-21
US10155800B2 (en) 2018-12-18
CY1124024T1 (el) 2022-03-24
US20130089550A1 (en) 2013-04-11
ES2586579T3 (es) 2016-10-17
CN106432473B (zh) 2021-04-02
ES2826894T3 (es) 2021-05-19
WO2011103584A3 (en) 2012-07-12
SI2536745T1 (sl) 2016-10-28
US11254727B2 (en) 2022-02-22
HRP20160938T1 (hr) 2016-10-07
JP5705242B2 (ja) 2015-04-22
CA2790487A1 (en) 2011-08-25
HRP20201614T1 (hr) 2020-12-11
AU2011217770A1 (en) 2012-09-06
US20220348634A1 (en) 2022-11-03
HUE050768T2 (hu) 2021-01-28
WO2011103584A9 (en) 2012-08-16
US8629113B2 (en) 2014-01-14

Similar Documents

Publication Publication Date Title
RS61136B1 (sr) Novi ctla4-ig imunoadhezini
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
GB201008134D0 (en) Compounds
IL221371A0 (en) Anti-lrp6 antibodies
GB201015949D0 (en) Compounds
HK1194388A1 (zh) 抗缺刻蛋白 抗體
GB201007347D0 (en) Compounds
PL2603528T3 (pl) Przeciwciała Fab-glikozylowane
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
EP2649050A4 (en) LINKS
GB201002563D0 (en) Compounds
EP2627788A4 (en) TESTS BASED ON MICROVESICLES
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002216D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201021494D0 (en) Compounds
GB201013507D0 (en) Compounds
GB201005062D0 (en) Antibodies
GB201020751D0 (en) Antibodies
GB201005821D0 (en) Immunomoduatory compounds
GB201014392D0 (en) Compounds